Implementation date
May 2, 2024
At-a-glance
The OPTN Computer System, known as UNetSM, no longer requires transplant hospitals and histocompatibility labs to provide approvals of candidate’s unacceptable antigens when the candidate’s calculated CPRA is above 98%.
All candidates with a CPRA above 98% continue to be prioritized on the match appropriately, regardless of documentation status prior to implementation.
What you need to do
Transplant hospitals and histocompatibility labs are no longer required to obtain signatures and update candidate registrations when a candidate’s CPRA is above 98%. There are no changes needed for OPOs.
Additional details
The system changes to UNet include:
- The OPTN Waiting List, known as WaitlistSM, has been updated to no longer collect the transplant program’s HLA laboratory director and transplant physician or surgeon’s name when candidate’s CPRA is above 98%
- My Critical Data (on the UNet Secure Enterprise landing page) and Expected data (on Waitlist’s landing page) no longer includes a section for “Kidney Candidates Requiring Written Approvals for CPRA Greater Than 98%”
- Waitlist Reports:
- “CPRA greater than 98% approvals report” has been removed from Waitlist Reports
- Custom reports within Waitlist no longer include the approver names within the list of available columns
- Approver name(s) have been removed from any saved custom reports automatically at implementation
